532 related articles for article (PubMed ID: 9023264)
21. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes.
Hall H; Wedel I; Halldin C; Kopp J; Farde L
J Neurochem; 1990 Dec; 55(6):2048-57. PubMed ID: 1977888
[TBL] [Abstract][Full Text] [Related]
22. [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors].
Futamura T; Ohashi Y; Yano K; Takahashi Y; Haga K; Fukuda T
Nihon Yakurigaku Zasshi; 1996 May; 107(5):247-53. PubMed ID: 8690306
[TBL] [Abstract][Full Text] [Related]
23. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.
Primus RJ; Thurkauf A; Xu J; Yevich E; McInerney S; Shaw K; Tallman JF; Gallagher DW
J Pharmacol Exp Ther; 1997 Aug; 282(2):1020-7. PubMed ID: 9262371
[TBL] [Abstract][Full Text] [Related]
24. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
Andersen PH
Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
[TBL] [Abstract][Full Text] [Related]
26. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum.
Lee H; Tarazi FI; Chakos M; Wu H; Redmond M; Alvir JM; Kinon BJ; Bilder R; Creese I; Lieberman JA
Life Sci; 1999; 64(18):1595-602. PubMed ID: 10328519
[TBL] [Abstract][Full Text] [Related]
27. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.
Fitzgerald LW; Deutch AY; Gasic G; Heinemann SF; Nestler EJ
J Neurosci; 1995 Mar; 15(3 Pt 2):2453-61. PubMed ID: 7891180
[TBL] [Abstract][Full Text] [Related]
28. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
Malmberg A; Jackson DM; Eriksson A; Mohell N
Mol Pharmacol; 1993 May; 43(5):749-54. PubMed ID: 8099194
[TBL] [Abstract][Full Text] [Related]
29. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
30. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex.
Kusumi I; Ishikane T; Matsubara S; Koyama T
J Neural Transm Gen Sect; 1995; 101(1-3):231-5. PubMed ID: 8695053
[TBL] [Abstract][Full Text] [Related]
32. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Seeman P; Tallerico T
Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
[TBL] [Abstract][Full Text] [Related]
33. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat.
Rupniak NM; Hall MD; Mann S; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
Biochem Pharmacol; 1985 Aug; 34(15):2755-63. PubMed ID: 4040370
[TBL] [Abstract][Full Text] [Related]
34. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
[TBL] [Abstract][Full Text] [Related]
35. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.
Vile JM; D'Souza UM; Strange PG
J Neurochem; 1995 Feb; 64(2):940-3. PubMed ID: 7830089
[TBL] [Abstract][Full Text] [Related]
36. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
37. In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1988; 73(2):87-100. PubMed ID: 2974879
[TBL] [Abstract][Full Text] [Related]
38. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Joyce JN
Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025
[TBL] [Abstract][Full Text] [Related]
39. Are striatal dopamine D4 receptors increased in schizophrenia?
Reynolds GP; Mason SL
J Neurochem; 1994 Oct; 63(4):1576-7. PubMed ID: 7931313
[TBL] [Abstract][Full Text] [Related]
40. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
